Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates
by Zacks Equity Research
Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
by Zacks Equity Research
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.
Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
The Zacks Analyst Blog Highlights: Pfizer, Intel, HCA Healthcare, Xilinx and Cummins
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Intel, HCA Healthcare, Xilinx and Cummins
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
by Kinjel Shah
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress
by Swarup Gupta
The index traversed a mixed week, buoyed by encouraging earnings numbers and dragged lower by comments from the Fed Chair.
Top Stock Reports for Pfizer, Intel & HCA Healthcare
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Intel (INTC) and HCA Healthcare (HCA).
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates for the first quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure
by Zacks Equity Research
Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.
Q1 Earnings Continue
by Zacks Equity Research
Q1 Earnings Continue
Big Day for Q1 Earnings: MCD, PFE, GE & More
by Mark Vickery
After today's close, we will hear from Apple Inc. (AAPL). This morning, here are a few of the big names reporting.
Pfizer (PFE) Beats on Q1 Earnings & Sales, Raises EPS View
by Zacks Equity Research
Pfizer (PFE) beat estimates for first-quarter earnings and sales and raised the mid-point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full-year sales.
Teladoc (TDOC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc's (TDOC) Q1 earnings should benefit from increase in revenues, partly offset by rise in expenses.
Is a Beat in Store for Cigna (CI) This Earnings Season?
by Zacks Equity Research
Cigna's (CI) Q1 earnings should benefit from increase in revenues and membership.
Why Earnings Season Could Be Great for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.
Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong performance of Eliquis and Opdivo.
What's in Store for SS&C Technologies (SSNC) in Q1 Earnings?
by Zacks Equity Research
SS&C Technologies (SSNC) efforts to strengthen its cloud-based and AI technologies are likely to drive the top line.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $39.46, marking a +0.09% move from the previous day.
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches